GALFLUX FDT

Composition:
Each fast-disintegrating GALFLUX® FDT tablet contains 10 mg of Domperidone.

Pharmacology:
Domperidone is a dopamine antagonist with antiemetic activity. The antiemetic effect is due to a combination of peripheral (gastrokinetic) effects and antagonism of dopamine receptors in the chemoreceptor trigger zone, located outside the blood-brain barrier in the area postrema. Oral administration of Domperidone increases the duration of antral and duodenal contractions, increases gastric emptying of liquid and semisolid forms in healthy individuals, and solid forms in patients with delayed emptying, and increases pressure on the lower esophageal sphincter in healthy individuals.

Indications:
1. Acute nausea and vomiting. Routine prevention of vomiting after surgery is not recommended.
2. Nausea and vomiting caused by the administration of levodopa and bromocriptine. It is recommended that treatment with Domperidone should not exceed 12 weeks.
3. Treatment of symptoms of functional dyspepsia. Not recommended for long-term use.
4. Nausea and vomiting caused by cancer chemotherapy and radiotherapy.

Dosage and Administration:
Functional dyspepsia
Adults and elderly: 10-20 mg, 3 times daily and 10-20 mg before bedtime, depending on clinical response.
Treatment should not exceed 12 weeks.
Nausea and vomiting (including that caused by levodopa and bromocriptine)
Adults and elderly: 10-20 mg, administered every 4-8 hours. Children, associated with cancer chemotherapy and radiotherapy: 0.2-0.4 mg/kg/day, administered every 4-8 hours.
The medication should be taken 15-30 minutes before meals and at bedtime. GALFLUX® FDT is a fast-disintegrating tablet and can be swallowed without water.

Presentation and Registration Number:
GALFLUX® FDT Box, 5 strips @ 10 fast-disintegrating tablets. Reg. No. DKL2308027881A1

Categorised in:

This post was written by admin